Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5192903
Max Phase: Preclinical
Molecular Formula: C22H19FN2O3
Molecular Weight: 378.40
Associated Items:
ID: ALA5192903
Max Phase: Preclinical
Molecular Formula: C22H19FN2O3
Molecular Weight: 378.40
Associated Items:
Canonical SMILES: COc1cccc(CN2CCOc3cc(-c4ccc(F)nc4)ccc3C2=O)c1
Standard InChI: InChI=1S/C22H19FN2O3/c1-27-18-4-2-3-15(11-18)14-25-9-10-28-20-12-16(5-7-19(20)22(25)26)17-6-8-21(23)24-13-17/h2-8,11-13H,9-10,14H2,1H3
Standard InChI Key: OENYYMXIIDSLLD-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 378.40 | Molecular Weight (Monoisotopic): 378.1380 | AlogP: 3.93 | #Rotatable Bonds: 4 |
Polar Surface Area: 51.66 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.48 | CX LogD: 3.48 |
Aromatic Rings: 3 | Heavy Atoms: 28 | QED Weighted: 0.65 | Np Likeness Score: -1.06 |
1. Li Y, Zhang L, Yang R, Qiao Z, Wu M, Huang C, Tian C, Luo X, Yang W, Zhang Y, Li L, Yang S.. (2022) Discovery of 3,4-Dihydrobenzo[f][1,4]oxazepin-5(2H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects., 65 (3.0): [PMID:34985886] [10.1021/acs.jmedchem.1c00672] |
Source(1):